Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22497173 | 1.00 | ADORA2A (0.37) | ADORA2AADORA1ADORA2BCPB2LMNA | |
| SCHEMBL20761642 | 1.00 | ADORA2A (0.37) | ADORA2AADORA1ADORA2BCPB2LMNA | |
| SCHEMBL22524860 | 0.80 | TGFBR1 (0.31) | — | |
| SCHEMBL31487985 | 0.78 | CYP2E1 (0.40) | CPB2CPB1 | |
| SCHEMBL22524780 | 0.73 | MEN1 (0.31) | — | |
| SCHEMBL20757533 | 0.72 | KDM5A (0.44) | — | |
| SCHEMBL6673526 | 0.72 | ADA (0.44) | ADORA2AADORA1CPB2LMNASMN1; SMN2 | |
| SCHEMBL20754559 | 0.70 | — | — | |
| SCHEMBL26660697 | 0.70 | BRD4 (0.40) | ADORA2AADORA1ADORA2BCPB2LMNA | |
| SCHEMBL26660693 | 0.70 | BRD4 (0.40) | ADORA2AADORA1ADORA2BCPB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-03-12 | — | — | US | disclosed |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-08 | — | — | US | disclosed |
| CN-111315733-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019034693-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317637-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, PYCARD | ADORA2A 767/4885ADORA1 1185/4885ADORA2B 2247/4885 |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | ADORA2A 1415/4885ADORA1 569/4885ADORA2B 2081/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | ADORA2A 944/4885ADORA1 1352/4885ADORA2B 1999/4885 |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | ADORA2A 2057/4885ADORA1 1741/4885ADORA2B 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.